Monthly Communication Report

Organization:	Innovative Medicines Canada/Médicaments novateurs Canada
Associated registration:	957857-371-128
Communication date:	2025-10-21
Posted date:	2025-11-12

Designated Public Office Holders who participated in the communication:	Burton Bailey, Member of Parliament House of Commons
List of Details Subject matter Detail Consumer Issues, Federal-Provincial Relations, Health, Intellectual Property, Research and Development, Science and Technology, Taxation and Finance Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH) Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Free trade agreements as they relate to the biopharmaceutical industry Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Health, Research and Development, Science and Technology Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Federal-Provincial Relations, Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, National Security/Security, Research and Development, Science and Technology Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Responsible Officer who filed this communication report:	Bettina Hamelin
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.